Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC ...

Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

"Antihypertensive medication administration time did not affect the risks and benefits of blood pressure-lowering medication ...

Long-term human albumin therapy failed to significantly improve long-term survival outcomes in cirrhotic patients with acute ...

Like many of the almost 100,000 medical students in the U.S., I enrolled in medical school having grown up infatuated with ...

President Trump on Monday signed a sweeping executive order setting a 30-day deadline for drugmakers to lower the cost of ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

The FDA and NIH announced a joint nutrition research venture to better understand the causes of diet-related chronic disease, ...

Means argues that the cause of most health conditions -- including cancer, Alzheimer's disease, obesity, erectile dysfunction ...

Early findings from the SPARTAN phase II trial, presented at the National Kidney Foundation (NKF) Spring Clinical Meeting, ...

Tacrolimus outshined another immunosuppressive drug at extending relapse-free survival in kids with frequently relapsing or ...